Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed
CAMBRIDGE, MA, USA I May 16, 2019 I Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the first clinical results from its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate. Genocea employs its ATLAS™ platform for patient-specific neoantigen selection, using each patient’s own T cells to identify the neoantigens to which each patient mounts anti-tumor cytokine responses.
“To date, we have analyzed full immune response data from three patients following their priming series of three vaccinations and have detected immune responses to 93% of the total administered neoantigens, a response rate that would be best-in-class if seen across the full vaccinated cohort,” said Tom Davis, M.D., Genocea’s Chief Medical Officer. “We are studying a diverse group of patients and, despite this variability, we are seeing consistently broad immune responses, including ex vivo CD8+ T cell responses, which have not previously been detected after monotherapy with a neoantigen vaccine. We expect to present more detailed immunogenicity and safety data from these and additional patients at the upcoming meeting of the American Society of Clinical Oncology (ASCO).”
ASCO POSTER SESSION: Developmental Immunotherapy and Tumor Immunobiology
Poster Board: #255 • *Abstract 2611
Title: A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses
Presenter: Roger B. Cohen, M.D., University of Pennsylvania Perelman School of Medicine
Date: Saturday, June 1, 8:00 AM – 11:00 AM Central Time
Location: Hall A
*Note: The abstract was submitted prior to the availability of the immunogenicity data being reported today.
Conference Call and Webcast – June 3rd at 8:30 am ET
Genocea will host a conference call and webcast to discuss the clinical results presented at ASCO at 8:30 am ET on June 3, 2019. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 9068006. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
About Genocea Biosciences, Inc.
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit www.genocea.com
SOURCE: Genocea Biosciences
